Evidence map›Paper›PMID 39076979›Full record

ArticleFrontiers in immunology2024

Comparison of "framework Shuffling" and "CDR Grafting" in humanization of a PD-1 murine antibody.

Yongmei Wang, Yi-Li Chen, Hui Xu, Gul E Rana, Xiaorong Tan, Mengying He, Qingqing Jing, Qi Wang, Guifeng Wang, Zuoquan Xie and 1 more

Abstract readComparative Study
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yongmei Wang *Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Yi-Li Chen *Dartsbio Pharmaceuticals Ltd., Zhongshan, Guangdong, China.
Hui Xu *Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Gul E RanaShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Xiaorong TanShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Mengying HeShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Qingqing JingAntibody Development Department, Shanghai Genechem Co., Ltd., Shanghai, China.
Qi WangShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Guifeng WangShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Zuoquan XieShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Chunhe WangShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Humanization is typically adopted to reduce the immunogenicity of murine antibodies generated by hybridoma technology when used in humans. Methods: Two different strategies of antibody humanization are popularly employed, including "complementarity determining region (CDR) grafting" and "framework (FR) shuffling" to humanize a murine antibody against human programmed death-1 (PD-1), XM PD1. In CDR-grafting humanization, the CDRs of XM PD-1, were grafted into the human FR regions with high homology to the murine FR counterparts, and back mutations of key residues were performed to retain the antigen-binding affinities. While in FR-shuffling humanization, a combinatorial library of the six murine CDRs in-frame of XM PD-1 was constructed to a pool of human germline FRs for high-throughput screening for the most favorable variants. We evaluated many aspects which were important during antibody development of the molecules obtained by the two methods, including antibody purity, thermal stability, binding efficacy, predicted humanness, and immunogenicity, along with T cell epitope prediction for the humanized antibodies. Results: While the ideal molecule was not achieved through CDR grafting in this particular instance, FR-shuffling proved successful in identifying a suitable candidate. The study highlights FR-shuffling as an effective complementary approach that potentially increases the success rate of antibody humanization. It is particularly noted for its accessibility to those with a biological rather than a computational background. Discussion: The insights from this comparison are intended to assist other researchers in selecting appropriate humanization strategies for drug development, contributing to broader application and understanding in the field.

Indexed as

Complementarity Determining RegionsProgrammed Cell Death 1 ReceptorAnimalsAntibodies, Monoclonal, HumanizedEpitopes, T-LymphocyteHumansMiceAntibodies, Monoclonal, HumanizedComplementarity Determining RegionsEpitopes, T-LymphocytePDCD1 protein, humanProgrammed Cell Death 1 Receptorantibody humanizationCDR graftingFR shufflingimmunogenicityprogrammed death-1

Identifiers

PMID39076979
PMCPMC11284016

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.